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ill describe two case studies of successful HIV/AIDS hospice
rograms in Southeast Asia.
oi:10.1016/j.ijid.2008.05.137
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merging Infections: What Have We Learned After
5 Years?
. Heymann
WHO, Geneva, Switzerland
nfectious diseases are complex, dynamic, and constantly
volving. Examples during the past 15 years range from
hanges in transmission patterns of human monkeypox
nd dengue; more frequent re-emergence of cholera,
egionnaire’s disease, E. coli 0157, hepatitis C and, the
aemorrhagic fevers - Marburg, Lassa and Ebola; and emer-
ence of bovine spongiform encephalopathy (BSE), severe
cute respiratory syndrome (SARS) and H5N1 inﬂuenza.
Causes of emergence and re-emergence include weak-
ned public health infrastructure, increases in human
nd domestic animal populations, rapid urbanization, and
ffects on the environment from global warming to defor-
station and ﬂooding. Human behavior also plays a major
ole, ranging from unsafe sexual practices to over- or
nder-prescribing of antimicrobial drugs, patient adher-
nce, unregulated sale, and indiscriminate use in humans,
lants and animals.
Emerging and re-emerging infections occur in a world
here international travel and trade facilitate their spread,
nd where their impact affects economies as well as health.
ttempts at regulation to prevent their international spread
ccurred ﬁrst in the 14th century quarantines in Venice.
hey continued during the 19th and 20th centuries in Europe
nd the Americas through a series of conferences and con-
entions leading to the International Health Regulations.
he goal of the Regulations is to strengthen national capac-
ties to detect and respond to emerging or re-emerging
nfections when and where they occur, with the guarantee
f a safety net of collective detection and response should
hey cross international borders.
The lesson over the past 15 years - whether from
he global response to SARS or preparations for the next
nﬂuenza pandemic - is that collective action will decrease
ur vulnerability, and increase our public health security.
he challenge is to ensure resources for our collective action
nder the framework of the International Health Regula-
ions.
oi:10.1016/j.ijid.2008.05.138
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ow to Evaluate Response to Treatment in AOM
.P. McCormick
University of Texas Medical Branch at Galveston, Galveston,
X, USA
ackground: Several studies have shown that watchful wait-
ng management of acute otitis media (AOM) can be an
lternative to immediate antibiotics. In practice, clinicians
ay be more comfortable using the watchful waiting option
hen the child has mild symptoms and the ear is not severely
nﬂamed. Regarding clinical trials, standardized criteria for
he diagnosis of AOM, and a clear description of TM ﬁnd-
ngs has often been lacking, making interpretation of study
esults somewhat difﬁcult. The objective of this paper will
e to deﬁne AOM, review the development of an Ear Card
ethodology for assessing the child with AOM, and describe
he effective use of the Ear Card in a clinical trial.
Methods: The Ear Card system for assessing the child with
OM was evaluated for concurrent correlation, sequence
alidity and reliability against previously published question-
aires. Responsiveness was assessed during a randomized
linical trial.
Results: The system demonstrated excellent sequence
alidity, concurrent correlation and reliability.
Conclusions: The Ear Card combines a parent assessment
f severity using a faces scale and the clinician’s assessment
f the tympanic membrane to provide an evaluation of total
OM severity that can be used to characterize AOM signs and
ymptoms at enrollment and to evaluate a patients progress
uring treatment. For research, clinical investigators can be
eliably trained using the Ear Card, so that clinical charac-
eristics at enrollment and follow-up can be clearly deﬁned
nd scored. The method is sufﬁciently sensitive to detect
mall differences in outcomes between treatment groups.
he Ear Card has also been useful in teaching residents and
tudents to accurately assess the tympanic membrane.
Clinicians, AOM researchers, and clinical educators from
round the world have requested our copyrighted electronic
ersion of the Ear Card, which may be freely used for patient
are, teaching and research.
oi:10.1016/j.ijid.2008.05.139
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ummary of Studies With New Antibiotics in AOM in Last
ecade - Where Are We?
. Arguedas
Instituto de Atención Pediátrica, San Jose, Costa Rica
n the last decade multiple clinical antimicrobials with new
ntibiotics have been performed in children. During this
ime, the design of the clinical trial improved dramati-
ally to take into consideration multiple factors but always
eeping as the most critical factor the resolution of signs
nd symptoms from the participant children. In this regard,
rial have taking into consideration the use of innovative
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additional surrogate markers such as the value of a during
treatment second tympanocentesis, the impact of the study
medication on the nasopharygeal ﬂora and more recently
the parents and children response to speciﬁc questions as a
way to evaluate time to clinical resolution between agents
or against placebo. Importantly, clinical trials have focus on
those children that most likely require antimicrobial therapy
either because they have a recurrent otitis media or they are
therapeutic failures to standard OM therapy making these
two set of patients at high risk of having a resistant pathogen
in the affected middle ear. Completed clinical trials have
been presented or published in peer review journals with the
main focus been the impact of these new compounds against
resistant S. pneumoniae strains and against the other target
MEF pathogens. In this regard, some of the trial that were
performed and that will be described in detail in the pre-
sentation, include a study using single dose azythormycin,
a regimen approved by the FDA but with current large lim-
itation because of the rates of macrolide resistance; a high
dose twice a day cefdinir that showed disappointing results
against resistant S. pneumoniae and for H. inﬂuenzae; a
new azythromycin formulation used as a larger dose that
showed low eradication rates against macrolide resistant
S. pneumoniae but a better eradication rate against H.
inﬂuenzae; a recently completed trial with an oral carpa-
penem (faropenem) [results pending] and multiple trials
with two promising quinolones for these problematic chil-
dren presented as a pediatric formulation (gatiﬂoxacin and
levoﬂoxacin) that showed a tremendous success but whose
programs were put on hold by the sponsors. A pediatric
program with telithromycin, a new ketolide with excellent
invitro activity against penicillin and macrolide resistant
S. pneumoniae was also put on hold by the sponsor. Cur-
rently the number of trials for otitis media are extremely
limited however there are children with problematic antimi-
crobial resistant pathogens that need research programs in
this area.
doi:10.1016/j.ijid.2008.05.140
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What Do Antibiotics Really Do In AOM?
R. Dagan
Ben-Gurion University of the Negev and Soroka University
Medical Center, Beer-Sheva, Israel
It is well recognized that appropriately chosen antibiotics
enhance bacteriologic eradication in culture-positive AOM.
It is also established that if bacteriologic eradication does
not occur within 3—5 days of treatment, the risk of clinical
failure at the end of the treatment increases ∼ 5 fold. How-
ever, even with the 5-fold increase, over 50% of those from
whom organisms were not eradicated after 3—5 days are still
doing well at the end of treatment. New evidence demon-
strates that among those who, despite failure of eradication
after 3—5 days of treatment, have clinical improvement or
cure at the end of treatment, recurrence of AOM occurs 35%
more frequently than among those with eradication. Fur-
thermore, in these cases only 34% will have new organisms,
vs. 64% among those from whom bacteria were eradicated.
New evidence also shows that nasopharyngeal (NP) carriage
s
a
a
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t initiation and/or at end of treatment is an independent
ajor determinant of the outcome of AOM, with an indepen-
ent additional role to that of MEF organisms. Antibiotics
ere shown to modify NP carriage at the end of treatment
nd thus play a major role in determining the nature of
he following AOM in children. Thus, although the long term
eneﬁts of antibiotic use in AOM are not proven, the short
erm problems were demonstrated. This should be carefully
eighted when deciding to treat a child with AOM.
oi:10.1016/j.ijid.2008.05.141
9.004
elayed Antibiotic Treatment of AOM - Risks and Beneﬁts
. Little
University of Southampton, Southampton, United Kingdom
elayed prescribing can take many forms but the Dutch
riginally developed the policy: their guidance was for no
rescription for AOM unless there was signiﬁcant otaligia
nd/or fever 72 hours after seeing the doctor, or if a pro-
onged discharge developed. They have shown in a large
ohort study that if such an approach is used there are likely
o be very few cases of complications. Delayed prescrib-
ng can help rationalise antibiotic use (with reductions in
ntibiotic use from 50—75%); changes beliefs in antibiotics
since prescribing antibiotics probably fuels a vicious circle
f belief in antibiotics, subsequent reattendance, further
ntibiotic use etc.; achieves acceptable symptom control;
nd provides a back up and rapid access to antibiotics where
here is uncertainty about which children will not recover
uickly. There is weak ecological evidence from the UK and
uropean studies that either localities or countries that have
ower prescribing of antibiotics have higher admission rates
or mastoiditis. Even assuming such ecological data does
rovide secure evidence of a genuine problem, the data sug-
ests that several thousand prescriptions would be required
o prevent one case of mastoiditis in afﬂuent developed
opulations. The alternatives to delayed prescribing are all
roblematic: not to prescribe at all which is probably less
afe; to prescribe in most or all cases which will lead to
ide effects, antibiotic resistance, and possibly more com-
lications associated with antibiotic resistance; or to target
ntibiotics those likely to suffer prolonged illness or adverse
vents - but few clinical studies demonstrate such at risk
roups, nor the beneﬁt of antibiotics in such groups. Delayed
rescribing can either be implemented in a number of ways
commonly by giving parents access to a prescription with
lear guidance, or not to prescribe but advise patients to
eturn for review if they are getting worse or not improving.
he latter option provides the clinician with more control,
ut may result in higher reconsultation rates, and for no
lear beneﬁt.
Conclusion: Based on current evidence delayed pre-
cribing has its place. If parents are provided with clear
nformation - about the timing of antibiotic use, and what
hould trigger review, it is acceptable to parents, is reason-
bly safe, and provide a signiﬁcant help in the battle against
ntibiotic resistance.
oi:10.1016/j.ijid.2008.05.142
